We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 501

Dependent claims give rise to improper broadening reissue
  • Foley & Lardner LLP
  • USA
  • May 27 2015

In ArcelorMittal France v. AK Steel Corp., the Federal Circuit found that the addition of a dependent claim to a reissue application improperly


Patent safe harbor applies to supplemental new drug applications
  • Foley & Lardner LLP
  • USA
  • May 21 2015

On May 13, 2015, the Federal Circuit confirmed in Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc. that the safe harbor provisions of 35 U


Federal Circuit finds no direct infringement of Akamai patents
  • Foley & Lardner LLP
  • USA
  • May 19 2015

The Federal Circuit issued its remand decision in Akamai Technologies, Inc. v. Limelight Networks, Inc., this time affirming the district court


The importance of contracts for joint infringement in patent cases
  • Foley & Lardner LLP
  • USA
  • May 19 2015

It has been about a year since the Supreme Court rendered its decision in Limelight v. Akamai regarding induced infringement for methods performed by


First look at false marking under the AIA
  • Foley & Lardner LLP
  • USA
  • May 14 2015

In Sukumar v. Nautilus, Inc., the Federal Circuit took its first look at the standing requirements to bring a false marking case under the American


California Supreme Court scrutinizes reverse payment ANDA settlements
  • Foley & Lardner LLP
  • USA
  • May 12 2015

In In Re Cipro Cases I & II, the California Supreme Court laid out a four-part rule of reason analysis for evaluating ANDA settlements that involve a


Biosig claims pass reasonable certainty test
  • Foley & Lardner LLP
  • USA
  • April 28 2015

In its decision on remand from the Supreme Court, the Federal Circuit once again held the Biosig patent claims not indefinite, reversing the district


Amicus briefs on biosimilar patent litigation
  • Foley & Lardner LLP
  • USA
  • April 23 2015

Amgen has appealed the district court decision denying its motion for a preliminary injunction to keep Sandoz' biosimilar version of Neupogen off


Apotex has standing despite Benicar patent disclaimer
  • Foley & Lardner LLP
  • USA
  • April 9 2015

In Apotex Inc. v. Daiichi Sankyo, Inc., the Federal Circuit held that Apotex has standing to seek a declaratory judgment that it does not infringe


Waiting on Sequenom
  • Foley & Lardner LLP
  • USA
  • April 7 2015

As I write this there’s a voice in my head saying, “Be careful what you wish for!” but it has been five months since Sequenom was argued at the